tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Mar;18(3):e13272.
doi: 10.1111/irv.13272. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2
Quentin Richier[SUP] 1 [/SUP], Benjamin De Valence[SUP] 1 [/SUP], Dorothée Chopin[SUP] 1 [/SUP], Emmanuelle Gras[SUP] 1 2 [/SUP], Laura I Levi[SUP] 1 2 [/SUP], Yasmine Abi Aad[SUP] 1 [/SUP], Jérôme Pacanowski[SUP] 1 [/SUP], Jean-Luc Meynard[SUP] 1 [/SUP], Léo Plaçais[SUP] 3 [/SUP], Dorothée Fey[SUP] 1 [/SUP], Priscille Couture[SUP] 4 [/SUP], Guillaume Martin-Blondel[SUP] 5 6 7 [/SUP], Vincent Pestre[SUP] 8 [/SUP], Juliette Woessner[SUP] 8 [/SUP], Sophie Ancellin[SUP] 9 [/SUP], Pierre Weyrich[SUP] 10 [/SUP], Benjamin Carpentier[SUP] 10 [/SUP], Salim Idri[SUP] 11 [/SUP], Pierre Tiberghien[SUP] 12 13 [/SUP], Laure Surgers[SUP] 1 2 [/SUP], Thomas Hueso[SUP] 14 [/SUP], Karine Lacombe[SUP] 1 2 [/SUP]
Affiliations
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.
Keywords: COVID-19; Omicron variant; SARS-CoV-2; convalescent plasma; immunocompromised.
. 2024 Mar;18(3):e13272.
doi: 10.1111/irv.13272. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2
Quentin Richier[SUP] 1 [/SUP], Benjamin De Valence[SUP] 1 [/SUP], Dorothée Chopin[SUP] 1 [/SUP], Emmanuelle Gras[SUP] 1 2 [/SUP], Laura I Levi[SUP] 1 2 [/SUP], Yasmine Abi Aad[SUP] 1 [/SUP], Jérôme Pacanowski[SUP] 1 [/SUP], Jean-Luc Meynard[SUP] 1 [/SUP], Léo Plaçais[SUP] 3 [/SUP], Dorothée Fey[SUP] 1 [/SUP], Priscille Couture[SUP] 4 [/SUP], Guillaume Martin-Blondel[SUP] 5 6 7 [/SUP], Vincent Pestre[SUP] 8 [/SUP], Juliette Woessner[SUP] 8 [/SUP], Sophie Ancellin[SUP] 9 [/SUP], Pierre Weyrich[SUP] 10 [/SUP], Benjamin Carpentier[SUP] 10 [/SUP], Salim Idri[SUP] 11 [/SUP], Pierre Tiberghien[SUP] 12 13 [/SUP], Laure Surgers[SUP] 1 2 [/SUP], Thomas Hueso[SUP] 14 [/SUP], Karine Lacombe[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38501337
- PMCID: PMC10949173
- DOI: 10.1111/irv.13272
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.
Keywords: COVID-19; Omicron variant; SARS-CoV-2; convalescent plasma; immunocompromised.